Redefining care for people with blood disorders

Jennifer Jarrett is Chief Executive Officer of Damora Therapeutics. She is a seasoned executive with nearly three decades of experience in corporate strategy, finance and investor relations, drug development, and organizational leadership. Most recently, she served as Chief Operating Officer of Arcus Biosciences, a development-stage oncology company. During her tenure, she also served as Chief Financial Officer and a member of the company’s Board of Directors. Prior to Arcus, Ms. Jarrett served as Vice President of Corporate Development and Capital Markets at Uber Technologies, Inc. Previously, she was Chief Financial Officer of Medivation, a commercial oncology company that developed the blockbuster medicine XTANDI® (enzalutamide) for prostate cancer, through the company’s acquisition by Pfizer. Ms. Jarrett spent 20 years in investment banking, including at Citigroup, where she ran the firm’s west coast life sciences investment banking practice, and prior to that at Credit Suisse and Donaldson, Lufkin & Jenrette. Ms. Jarrett received a B.A. in Economics from Dartmouth College and an M.B.A. from Stanford University Graduate School of Business. She serves on the boards of Sagimet Biosciences, Syndax Pharmaceuticals and Zura Bio.

Sherwin Sattarzadeh is Chief Operating Officer of Damora Therapeutics. He brings over 20 years of industry experience across the many facets and stages of drug development and company lifecycle. Most recently, Mr. Sattarzadeh served as Chief Business Officer at Blueprint Medicines. During his 10 years at Blueprint Medicines, he held positions of increasing responsibility, including Head of Regulatory Affairs, Chief of Staff, and SVP Strategic Operations. He has an extensive background in hematology/oncology and rare disease drug development, having led and contributed to the global approvals of AYVAKIT® (avapritinib), GAVRETO® (pralsetinib), CERDELGA® (eliglustat), and MOZOBIL® (plerixafor). Mr. Sattarzadeh received his M.B.A. from Boston University and holds a B.Sc. in Chemistry from the University of British Columbia.

Dr. Becker Hewes is Chief Medical Officer of Damora Therapeutics. Dr. Hewes brings over two decades of experience in drug development in public biotechnology companies. Most recently, he served as Chief Medical Officer at Blueprint Medicines. During his time at Blueprint Medicines, Dr. Hewes led the development of an industry-leading pipeline across mast cell disorders and solid tumors, including the approval of AYVAKIT (avapritinib) for indolent and advanced systemic mastocytosis. Prior to joining Blueprint Medicines, he had an illustrious career in hematology/oncology drug development, having led clinical development and translational medicine efforts for multiple early-stage oncology programs through clinical proof-of-concept, including Kisqali® (ribociclib), as well as leading registration programs for Bosulif® (bosutinib), and Torisel® (temsirolimus). Dr. Hewes received his B.S. from Vanderbilt University and an M.D. from Georgetown University. He completed his residency at New York Hospital/Cornell Medical Center and his fellowship training in Pediatric Oncology at Emory University.

Garrett Winslow brings more than 15 years of experience working with public companies in the life sciences industry. He previously served as the General Counsel of Galecto, Inc. and Spring Bank Pharmaceuticals, publicly listed clinical-stage biotechnology companies. Prior to that, he was a partner in the Corporate and Securities group at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. in Boston, Massachusetts, where he advised public and private companies on securities law compliance, corporate governance and transactional matters. Mr. Winslow received his Master’s in Taxation from Boston University Law School, J.D. degree from Suffolk University Law School, and B.A. degree in Business Administration from the University of Washington.

Lori Firmani has over 25 years of experience serving in financial roles in the biotech sector. She was appointed as Chief Financial Officer in November 2025 and prior to that served as Interim Chief Financial Officer and Vice President, Finance and Corporate Controller. Ms. Firmani served as Chief Financial Officer of Spring Bank Pharmaceuticals, Inc. from April 2020 until its acquisition in November 2020 and prior to that served in financial roles of increasing responsibility from January 2016 to April 2020. Ms. Firmani is a certified public accountant in the Commonwealth of Massachusetts and holds an M.B.A. from Babson College and a B.S. in accounting from the State University of New York at Geneseo.